Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model. Issue 1 (2nd January 2021)

• Record Type: Journal Article
• Authors: Safavi, Ashkan; Kefayat, Amirhosein; Mahdevar, Elham; Ghahremani, Fatemeh; Nezafat, Navid; Modarressi, Mohammad Hossein
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 1(2021)
• Page Start: 22
• Page End: 34
• Publication Date: 2021-01-02
• Subjects: Breast cancer -- peptide vaccine -- DNA vaccine -- cancer/testis antigen; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2020.1763693
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Multiepitope cancer vaccines have gained lots of attention for prophylactic and therapeutic purposes in cancer patients. In our previous study, multiepitope DNA and peptide cancer vaccines consisted of the most immunodominant epitopes of ACRBP and SYCP1 antigens were designed by bioinformatic tools. In this study, the effect of prophylactic co-immunization with these DNA and peptide cancer vaccines in the 4T1 breast cancer animal model was assessed. Serum levels of the peptide-specific IgG total, IgG2a and IgG1 were measured by enzyme-linked immunosorbent assay (ELISA). Also, the efficacy of the immunized mice splenocytes' for producing interleukin-4 (IL-4) and interferon-γ (IFN-γ) was evaluated. The co-immunization caused a significant ( P < .05) increase in the serum levels of IgG1 and IgG2a. The co-immunized mice splenocytes exhibited significantly enhanced IL-4 (6.6-fold) and IFN-γ (19-fold) production. Also, their lymphocytes exhibited higher proliferation rate (3-fold) and granzyme B production (6.5-fold) in comparison with the control. The prophylactic co-immunization significantly decreased the breast tumors' volume (78%) and increased the tumor-bearing mice survival time (37.5%) in comparison with the control. Taking together, prophylactic co-immunization with these multiepitope DNA and peptide cancer vaccines can activate the immune system against breast cancer. However, further experiments are needed to evaluate their efficacy from different angles.